Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study.

作者群：Xu J, Kato K, Raymond E, Hubner RA, Shu Y, Pan Y, Park SR, Ping L, Jiang Y, Zhang ., Wu X, Yao Y, Shen ., Kojima T, Gotovkin, E, Ishihara R, Wyrwicz L, Van Cutsem E, Jimenez-Fonseca. P, Lin CY (林振源), Wang L, Shi J, Li L, Yoon HH.

期刊：Lancet Oncol

出版年月：2023

圖片來源：Lancet Oncol

連結：https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00108-0/abstract